Inoperable liver cancer (HCC)
Clinical trial results with LENVIMA
Inoperable liver cancer and LENVIMA
While you may be overwhelmed right now, there are options that could help treat inoperable liver cancer (hepatocellular carcinoma, or HCC). If you’ve been diagnosed with HCC, your doctor may recommend LENVIMA, an FDA-approved therapy.
LENVIMA was studied in a clinical trial of 954 people with previously untreated HCC that could not be removed with surgery.
In this trial, patients were randomly assigned to receive either LENVIMA or sorafenib.
A clinical study of LENVIMA showed:
The median* time people treated with LENVIMA were alive was 14 months compared to 12 months for people treated with sorafenib. These results showed that treatment with LENVIMA was noninferior (not unacceptably worse) in comparison to sorafenib
*Median: The middle number in a list of numbers arranged from lowest to highest.
41% (194 out of 478 people) treated with LENVIMA had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 12% (59 out of 476 people) treated with sorafenib
194 of 478 people
had their tumors
shrink
LENVIMA
Partial Response: 39%
(184 of 478 people)
Complete Response: 2%
(10 of 478 people)
59 of 476 people
had their tumors
shrink
sorafenib
Partial Response: 12%
(55 of 476 people)
Complete Response: 1%
(4 of 476 people)
was the median* time people treated with LENVIMA did not have their cancer get worse compared to a median of 3.6 months for those treated with sorafenib
*Median: The middle number in a list of numbers arranged from lowest to highest.
How does LENVIMA work?
Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.